‘A victim of its own success’: Inside the great Ozempic shortage
The drug is approved in Australia to treat type 2 diabetes but people have flocked to it for weight loss. That’s raising some hard questions about who should receive it and why.
The world has fallen in love with Ozempic and its sister treatment, Wegovy.
Demand for these drugs has been so intense there is now a global shortage and regulators are cautioning people against buying fakes online. Lack of supply also has given rise to conflict and controversy about who should receive these injectable drugs.
Jill MargoSenior writerJill Margo is based in the Sydney office. Jill has won multiple prizes, including two Walkley Awards and is an adjunct associate professor at School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia. Connect with Jill on Twitter. Email Jill at jmargo@afr.com
